FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

2 weeks ago

Conditional approval extended through December 2026 for the treatment of CID in dogsCID confirmatory effectiveness trial expected to conclude in…

Modular Medical Announces Pricing of $4.68 Million Public Offering

2 weeks ago

SAN DIEGO, CA / ACCESS Newswire / December 10, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"),…

Modular Medical Announces Pricing of $4.68 Million Public Offering

2 weeks ago

SAN DIEGO, CA / ACCESS Newswire / December 10, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"),…

Aeroflow Health and Molina Healthcare Break Down Barriers to Nutrition and Diabetes Care in South Carolina

2 weeks ago

The new partnership expands nutrition counseling and DSME services for Molina Commercial and Medicare members statewide to support long-term health…

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

2 weeks ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

2 weeks ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

2 weeks ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

2 weeks ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

2 weeks ago

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant…

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

2 weeks ago

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant…